Charleston Laboratories

Daiichi Sankyo, Charleston Laboratories collaborate on hydrocodone products for pain

Monday, August 11, 2014

Daiichi Sankyo and Charleston Laboratories, through its wholly owned subsidiary LOCL Pharma, have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of opioid-induced nausea and vomiting (OINV).

[Read More]